# A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

> **NCT05519865** · PHASE2 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 118 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Tucidinostat
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05519865
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-26
- **Primary completion:** 2024-11-18
- **Final completion:** 2024-11-18
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05519865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05519865, "A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05519865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*